29
Participants
Start Date
April 30, 2005
Primary Completion Date
September 30, 2009
Study Completion Date
September 30, 2009
omalizumab
150-375 milligrams administered by subcutaneous injection every 2-4 weeks depending on body weight and serum IgE.
Placebo
150-375 milligrams depending on body weight and serum IgE.
Johns Hopkins Asthma and Allergy Center, Baltimore
Collaborators (1)
Genentech, Inc.
INDUSTRY
Johns Hopkins University
OTHER